Date: Thursday, November 6th, 2025
Time: 1:00pm – 2:00pm ET

WEBINAR TOPIC:

Jivi — With Them as They Grow™ Clinical Study Data for Children 7 to 11 Years.

OBJECTIVE:

This session provides a clinical review of safety and efficacy data drawn from both the PROTECT Kids and Alfa-PROTECT studies. Data from these studies have been combined, as each included participants aged 7 to less than 12 years. The studies were conducted to evaluate the safety and clinical effectiveness of Jivi in previously treated individuals within this age group who have severe hemophilia A. Get the latest data and learn how Jivi may fit the needs of your patients starting at age 7.

Indications: JIVI ® is a recombinant DNA-derived, Factor VIII concentrate indicated for use in previously treated adults and pediatric patients 7 years of age and older with hemophilia A (congenital Factor VIII deficiency) for:

• On-demand treatment and control of bleeding episodes.
• Perioperative management of bleeding.
• Routine prophylaxis to reduce the frequency of bleeding episodes.

Limitations of use JIVI is not indicated for use in:

• Children less than 7 years of age due to a greater risk for hypersensitivity reactions and/or loss of efficacy.
• Previously untreated patients (PUPs).
• Treatment of von Willebrand disease.

AUDIENCE:

All HTC Staff.

SPEAKER:

Dr. Akshat Jain MD, MPH

Director of Sickle Cell Center of Excellence; Faculty Clinical Medicine and Pediatrics; Hematology Oncology and Cell Therapy; Loma Linda University School of Medicine